Abstract
Prostacyclin and its derivatives are reported to decrease tumor metastases in several animal models. Potential mechanisms include the modulation of endothelial cell adhesion molecule expression, decreased adhesion of tumor cells to the subendothelial matrix, decreased tumor cell-platelet aggregation, decreased tumor cell-induced endothelial cell retraction, and decreased growth of micrometastases. The inhibition of cyclooxygenase-2 has been demonstrated to decrease the formation of colon adenomas and the development of colon carcinoma. Cancer chemoprevention trials using prostacyclin are underway. Thus, we hypothesized that patients receiving prostacyclin treatment are relatively protected from the development of metastatic malignancy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
